PHR — Phreesia, Inc.

Summary of Phreesia, Inc. Q4 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $127.1 million for Q4 2026, a 16% year-over-year increase; 7% growth excluding the AccessOne acquisition.
• Adjusted EBITDA: $29.4 million, up from $16.4 million in Q4 2025, representing a 23% margin.
• Average Healthcare Services Clients (AHSCs): Increased to 4,658, with 80 new clients from the AccessOne acquisition.
• Free Cash Flow: $28.5 million for Q4, up $19.3 million year-over-year, marking the strongest quarterly free cash flow to date.
• Net Income: Positive GAAP net income for the first time in the company's history.
• Cash Position: Cash and cash equivalents stood at $73.8 million as of January 31, 2026.

2. Strategic Updates and Business Highlights

• Acquisition of AccessOne: Central to the provider financing strategy, enhancing cash flow predictability for providers.
• Launch of ProviderConnect: Aimed at healthcare provider marketers, expanding Phreesia's offerings in HCP marketing.
• AI Integration: Increasing use of AI for operational efficiency, contributing to margin expansion.
• Focus Areas for FY 2027: Growth initiatives include scaling AccessOne, expanding HCP marketing, and further AI integration.

3. Forward Guidance and Outlook

• Revenue Guidance for FY 2027: Revised to $510 million - $520 million, down from $545 million - $559 million, reflecting reduced visibility into spending commitments from pharmaceutical manufacturers.
• Adjusted EBITDA Guidance: Maintained at $125 million - $135 million, indicating confidence in operational leverage despite revenue reductions.
• AHSC Growth Expectation: Mid-single-digit percentage growth anticipated for FY 2027, with total revenue per AHSC expected to grow in the low single-digit percentage range.

4. Bad News, Challenges, or Points of Concern

• Market Challenges: The healthcare industry is facing headwinds, including FDA guideline changes and reduced spending commitments from certain pharmaceutical clients, notably in Network Solutions.
• Visibility Issues: Shorter visibility into revenue forecasts, particularly in the second half of FY 2027, due to variability in client spending.
• Impact of External Dynamics: Specific therapeutic areas, such as vaccines and public health initiatives, have seen reduced spending, impacting revenue forecasts.

5. Notable Q&A Insights

• Network Solutions Dynamics: The decline in visibility is not broad-based but specific to certain brands and therapeutic areas. The company is monitoring fluid client budgets closely.
• ProviderConnect Contribution: While the launch was successful, it is still early, and its impact on revenue is currently minimal.
• Cost Management: The company is implementing efficiency measures, particularly through AI, to maintain EBITDA guidance despite revenue reductions.
• Long-term Strategy: Phreesia remains committed to its strategy of driving growth among providers with higher prescription dispensing rates, viewing current challenges as temporary.

Overall, Phreesia, Inc. reported strong financial performance for Q4 2026, achieving significant milestones while navigating a challenging healthcare market. The company remains focused on strategic growth initiatives and operational efficiencies as it moves into FY 2027.